Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Inhibrx Biosciences Inc (INBX)

133 + Investors. Track Smart Money conviction in INBX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -6
Streak
1Q ▼
Buyers last Q
55%

Smart Money Signals — INBX

Based on 134 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their INBX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (96% of max)

96% of all-time peak
134 hedge funds hold INBX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +43% more funds vs a year ago

fund count last 6Q
+40 new funds entered over the past year (+43% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 55% buying

79 buying64 selling
Last quarter: 79 funds bought or added vs 64 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-26 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 9 → 25 → 47 → 21. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

51% of holders stayed for 2+ years

■ 51% conviction (2yr+) ■ 22% medium ■ 26% new
69 out of 134 hedge funds have held INBX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
🚀

Acceleration phase — new buyers rushing in

12 → 9 → 25 → 47 → 21 new funds/Q
New funds entering each quarter: 9 → 25 → 47 → 21. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 64% veterans vs 26% newcomers

■ 64% veterans ■ 10% 1-2yr ■ 26% new
Entry-cohort mix of 144 holders: 92 (64%) are 2+ year veterans, 14 entered 1–2 years ago, and 38 (26%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 35% AUM from major funds

35% from top-100 AUM funds
40 of 131 holders rank in the top 100 by AUM, accounting for 35% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.3
out of 10
Moderate Exit Risk
Exit risk score 4.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — INBX

In 2026 Q1, 79 hedge funds were net buyers of INBX (21 opened a new position, 58 added to an existing one), while 64 reduced or exited (37 trimmed, 27 sold completely) — a 55% buyer ratio, indicating a slight buying edge. 35% of total institutional value in INBX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -6 funds (more exits than new entries). Total institutional holders: 134.

Hedge Fund Ownership: INBX

How many hedge funds hold INBX — quarterly history vs. share price
Quarterly hedge fund ownership of INBX vs. share price

Market Analysis: INBX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: INBX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Inhibrx Biosciences Inc (INBX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much INBX has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 46d ago
INBX
-6.7%
XLV
+5.5%

INBX outperformed XLV by -12.2% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 1d ago
INBX
+0.0%
XLV
+0.0%

Since the filing became public, INBX outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

18 top-rated funds 2 high-conviction
Consensus
5.6
/ 10
breadth
×
Elite
1.7
/ 10
conviction
Hedge Fund Positioning: INBX
2026 Q2 Stats Unlock in 4 days 133 + Investors

Track Smart Money conviction in INBX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 133 140 -5.0%
13F Shares 13M 14M -6.09%
Total Value $878M $1.10B -20.15%
New Positions 20 47 -27
Increased Positions 54 41 +13
Closed Positions 27 9 +18
Reduced Positions 36 37 -1
Total Calls 10 12 -16.67%
Total Puts 3 6 -50.0%
PUT/CALL Ratio 0.3 0.5 Bullish

Statistics: INBX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

133 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in INBX. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 INBX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Sanofi 20.54% 1,157,926 $109.7M
2 CDC Financial, Inc. 5.56% 140,130 $13.3M
3 PFM Health Sciences, LP 2.51% 308,385 $29.2M
4 Parkman Healthcare Partners LLC 2.49% 256,950 $24.3M
5 Perceptive Advisors LLC 1.85% 1,297,763 $123.0M
6 First Turn Management, LLC 1.67% 164,783 $15.6M
7 Cannon Global Investment Management, LLC 1.58% 5,900 $559K
8 Western Standard LLC 1.51% 47,000 $4.5M
9 Sofinnova Investments, Inc. 1.48% 303,103 $28.7M
10 CDC Financial, Inc. 1.19% 30,000 $2.8M
11 Hussman Strategic Advisors, INC. 0.69% 31,500 $3.0M
12 Viking Global Investors LP 0.30% 1,123,929 $106.5M
13 Persium Advisors, LLC 0.30% 4,875 $462K
14 Atom Investors LP 0.25% 29,594 $2.8M
15 Schonfeld Strategic Advisors LLC 0.24% 697,586 $66.1M
16 Marble Bar Asset Management LLP 0.23% 3,537 $335K
17 Informed Momentum Co LLC 0.19% 23,077 $2.2M
18 Opaleye Management Inc. 0.17% 20,291 $1.9M
19 Platinum Investment Management Ltd 0.14% 6,146 $582K
20 ArrowMark Colorado Holdings LLC 0.14% 35,176 $3.3M
21 Woodline Partners LP 0.12% 400,892 $38.0M
22 Nicholas Investment Partners, LP 0.11% 21,443 $2.0M
23 Voleon Capital Management LP 0.10% 58,358 $5.5M
24 Harvest Management LLC 0.10% 2,600 $246K
25 Empyrean Capital Partners, LP 0.09% 30,000 $2.8M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Inhibrx Biosciences Inc (INBX)

What does the Smart Money Trend signal show for INBX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their INBX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for INBX?

Slight buying edge — 55% buying: Last quarter: 79 funds bought or added vs 64 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for INBX holders?

Strong quality — 35% AUM from major funds: 40 of 131 holders rank in the top 100 by AUM, accounting for 35% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held INBX?

51% of holders stayed for 2+ years: 69 out of 134 hedge funds have held INBX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Inhibrx Biosciences Inc (INBX) following the 2026 Q2 hedge fund 13F filings?

As of today, INBX has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), INBX has gained -6.7% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →